Review
doi: 10.6004/jnccn.2010.0023.
An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma
Affiliations
- PMID: 20202464
- DOI: 10.6004/jnccn.2010.0023
Item in Clipboard
Review
An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma
J Natl Compr Canc Netw.
2010 Mar.
Abstract
A significant amount of literature is available on treatment monitoring and response assessment in lymphoma using FDG-PET, yet confusion exists concerning the potential and limitations of FDG-PET for determining the presence of residual disease during chemotherapy (interim FDG-PET). This article reviews the role of interim FDG-PET in 3 important scenarios: untreated diffuse large B-cell lymphoma, untreated Hodgkin lymphoma, and relapsed or refractory aggressive lymphoma in transplant-eligible patients, and provides recommendations on the use of this imaging modality in these settings.
Similar articles
-
An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.Semin Oncol. 2017 Dec;44(6):404-419. doi: 10.1053/j.seminoncol.2018.01.005. Epub 2018 Apr 22. Semin Oncol. 2017. PMID: 29935902 Review.
-
Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.Leuk Lymphoma. 2009 Nov;50(11):1750-2. doi: 10.3109/10428190903308080. Leuk Lymphoma. 2009. PMID: 19863179
-
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.Cancer. 2006 Dec 1;107(11):2678-87. doi: 10.1002/cncr.22276. Cancer. 2006. PMID: 17063502
-
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18. Int J Radiat Oncol Biol Phys. 2012. PMID: 22607911
-
Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.Blood Rev. 2015 Nov;29(6):417-25. doi: 10.1016/j.blre.2015.06.003. Epub 2015 Jun 17. Blood Rev. 2015. PMID: 26113144 Review.
Cited by
-
FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.Br J Cancer. 2011 Aug 9;105(4):498-504. doi: 10.1038/bjc.2011.274. Epub 2011 Jul 26. Br J Cancer. 2011. PMID: 21792197 Free PMC article.
-
Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.Acad Radiol. 2013 Sep;20(9):1122-9. doi: 10.1016/j.acra.2013.04.013. Acad Radiol. 2013. PMID: 23931426 Free PMC article.
-
Hodgkin's lymphoma therapy: past, present, and future.Expert Opin Pharmacother. 2010 Dec;11(17):2891-906. doi: 10.1517/14656566.2010.515979. Expert Opin Pharmacother. 2010. PMID: 21050034 Free PMC article. Review.
-
The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.Br J Haematol. 2015 Mar;168(6):845-53. doi: 10.1111/bjh.13219. Epub 2014 Nov 10. Br J Haematol. 2015. PMID: 25382494 Free PMC article.
-
Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients.Oncotarget. 2017 Jul 26;8(58):99104-99111. doi: 10.18632/oncotarget.19572. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228756 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
